# Novo Nordisk

Source: https://onco.cc/companies/da-novo/  
OnCo record `da-novo` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Novo Nordisk markets GLP-1 medicines for other indications and is testing semaglutide in Alzheimer’s EVOKE trials.

## Summary

Diabetes/obesity labels do not equal a dementia indication. EVOKE is investigational. Not investment advice.

## Fields

- Kind: Company
- Last checked: 2026-09-21
- Tags: dementia-atlas
- HQ: Bagsværd
- Type: pharma
- Website: https://www.novonordisk.com/

## Sources

- Novo Nordisk: https://www.novonordisk.com/

## Connected records

- drugs: [Semaglutide (EVOKE programme)](https://onco.cc/drugs/da-semaglutide-evoke/)
- trials: [EVOKE (semaglutide in early Alzheimer’s)](https://onco.cc/trials/da-trial-evoke/)
- diagnoses: [Alzheimer’s disease](https://onco.cc/diagnoses/alzheimers-disease/)

---
JSON: https://onco.cc/api/v1/entities/da-novo.json